Seeking Alpha

Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run...

Another antiviral drug maker focused on treating Hepatitis C that's experiencing a solid run higher today is Idenix Pharmaceutical (IDIX +11.5%). On Saturday, the company announced positive study results for its clinical-stage hep C drug candidates – IDX719 and IDX184, and presented updated cardiovascular safety and antiviral activity data from phase IIb studies of IDX184. The results were presented at the Annual Meeting for the American Association for the Study of Liver Diseases in Boston.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|